Introduction
Pathological aggregation of the microtubule-associated protein tau is a defining feature of many neurodegenerative diseases collectively called tauopathies (Ingram and Spillantini, 2002; Lee et al., 2001 ). An essential role of tau in these disorders became evident with the discovery that tau mutations cause inherited forms of FTD with parkinsonism linked to chromosome 17 (FTDP-17) (Hutton et al., 1998; Ingram and Spillantini, 2002; Lee et al., 2001) . The process of tau accumulation, paired helical filament (PHF) assembly, and aggregation is incompletely understood. While tau hyperphosphorylation clearly accelerates neurodegeneration (GrundkeIqbal et al., 1986; Kosik and Shimura, 2005; Lee et al., 1991) , the role of other posttranslational modifications, including proteolysis (Gamblin et al., 2003; Kosik and Shimura, 2005) , ubiquitination (Bancher et al., 1991; Gong et al., 2005; Iqbal and Grundke-Iqbal, 1991) , and nitration and glycosylation (Gong et al., 2005; Liu et al., 2002; Wang et al., 1996) , as well as the function of the tau amino terminus in this process, remain unclear (Amadoro et al., 2004; Chen et al., 2004; Gamblin et al., 2003) . A number of studies in vitro have identified potential proteases that are active against tau, including calpain, caspases, and thrombin (Arai et al., 2005; Gamblin et al., 2003; Mercken et al., 1995) . However, their relationship to neurodegeneration observed in tauopathy is not known. Thus, identification of genetic factors that influence tau aggregation or degradation in vivo and modulate tau-induced neurodegeneration would have important implications for understanding tau-induced neurodegeneration and designing potential therapeutic interventions (Kosik et al., 2002; Kosik and Shimura, 2005; Lee et al., 2001; Price et al., 1998; Santacruz et al., 2005) .
Here, we moved in a stepwise fashion from a largescale microarray gene expression experiment to functional confirmation and identification of a pathway of tau processing that impacts neurodegeneration (Figure 1 ). We performed a genetic screen in mice expressing a common, dominant FTD-causing mutation in human tau, and used microarrays to identify gene expression changes in different brain regions. A subset of the gene expression changes was validated by both Northern blot analysis and in situ hybridization (Figure 2 ). We then performed functional validation in a well-characterized Drosophila model of tauopathy (Jackson et al., 2002) , with particular focus on one of the genes, PSA (also known as Npepps), since it is a largely cytosolic aminopeptidase with very high expression in the CNS (McLellan et al., 1988; Tobler et al., 1997) . PSA also is involved in the degradation of neuropeptide transmitters in vitro (Safavi and Hersh, 1995) , but previously has not been demonstrated to affect tau. We found that PSA was upregulated in the cerebellum of mutant mice expressing the tau P301L transgene, and we hypothesized that since its expression was changed in a region relatively resistant to neurodegeneration, it might represent part of a transcriptional compensatory mechanism. We demonstrate that altering PSA expression has marked effects on tau-induced neurodegeneration in vivo in Drosophila. Reduced PSA expression increased neurodegeneration and tau aggregation, whereas overexpression of PSA inhibited neurodegeneration, concomitant with a reduction in tau immunoreactivity. These observations suggest that PSA can degrade tau in vivo via its aminopeptidase activity. We further confirmed that PSA catalyzes degradation of human tau in a cell-free system. Interestingly, Western blotting in human postmortem brain showed that PSA expression is higher in cerebellum than in frontal cortex in both FTD subjects and controls, suggesting a correlation between PSA levels and regional susceptibility to neurodegeneration that warrants further investigation.
Results
Regional Microarray Analysis of Tau P301L Mice We conducted a comprehensive regional microarray analysis of transgenic mice expressing human tau P301L (Lewis et al., 2000) , the most common human FTD mutation (Figure 1 ). These mice display many of the pathologic features of human tauopathies, including neurodegeneration in spinal cord and forebrain beginning between 7 and 9 months of age (Ishizawa et al., 2003; Lewis et al., 2000; Lin et al., 2003) . We compared gene expression in animals at 6 months of age, prior to the onset of a clinical phenotype or cell loss. At this stage, subtle biochemical abnormalities such as pathological tau phosphorylation can be identified in the absence of frank neurofibrillary tangles (NFT) and cell loss (Ishizawa et al., 2003; Lewis et al., 2000) . This approach provided two advantages: first, it minimized potential confounds, such as changes in gene expression due to altered cell composition or cell loss, or factors secondary to neurodegeneration, such as malnutrition (Geschwind, 2000; Mirnics, 2001; Mirnics and Pevsner, 2004) . Second, this approach made it more likely that we would identify biochemical changes during early phases of the neurodegenerative process that could potentially be more reversible than alterations identified during the later stages of disease. We also reasoned that some of the changes in gene expression occurring in brain regions relatively unaffected by neurodegeneration, such as the cerebellum, might reveal specific compensatory mechanisms that were involved in protecting that region. Thus, we performed a regional microarray analysis, comparing cerebral cortex, brainstem, cervical spinal cord, and cerebellum in transgenic and control nontransgenic animals using 24 Agilent Developmental mouse microarrays, which contain over 20,000 distinct probes. In each transgenic versus control comparison, three biological replicates, each representing at least three pooled littermates, were performed ( Figure 1) . A total of 31 probe sets that were differentially regulated between control and transgenic mice were identified using a combination of two analytic approaches; one was based on the false discovery rate, and the other was based on an empirically derived 99.5% confidence interval (Table 1) . Half of the gene expression changes identified, which comprised 16 genes (11 enriched in tau P301L animals and five enriched in control animals) (Table 1) , were found in the cerebellum.
We performed Northern blot analysis to provide quantitative confirmation of a randomly selected subset of six genes in independent nonlittermate animals of each genotype ( Figure 2B ). In all cases, the changes observed were significant (p < 0.01) and consistent with the microarray results. None of the changes were large, ranging between 1.5-and 2.5-fold, consistent with the mild phenotype at this stage. We also confirmed a subset of the changes by in situ hybridization in at least three independent nonlittermate animals of each genotype, confirming each of the differentially expressed genes tested (Figure 2 ). We specifically focused on confirming cerebellar expression changes, which were of particular interest as potential targets that could ameliorate tauopathy (e.g. , Figures 2A and 2C ; see below). Several genes were confirmed to be upregulated in cerebellum of mutant animals, including Bcl2, Gtpbp3, Rab9, and Psa, while others, such as Vegfa and Mel13, were downregulated in mutant animals ( Figure 2 ; up in control).
Several genes that were differentially expressed in brain regions more involved with neurodegeneration in human FTD and the mouse model, such as those differentially expressed in the brainstem or spinal cord, had been implicated previously in neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) Step 1: tissues were dissected from tau P301L and control nontransgenic animals.
Step 2: RNA was isolated and combined into tissueand litter-specific pools. RNA quality was verified prior to further experimentation.
Step 3: microarray hybridizations and data analysis were performed resulting in the list of candidate genes.
Step 4: identified gene expression changes were confirmed in independent animals. Expression of PSA was evaluated using in vitro and in vivo studies.
and AD. As an example, vesicle-associated membrane protein-associated protein B (Vapb) expression is altered in tau P301L brainstem, and mutations in the human Vapb gene result in spinal muscular atrophy and ALS (Nishimura et al., 2004) . Motor neuron disease resembling ALS is observed in a significant subset of FTD patients, including those with the P301L mutation (Lee et al., 2001; Lomen-Hoerth, 2004) . Thus, the identification of Vapb as a potential modifier of tauopathy provides a new potential molecular link between these conditions (Nishimura et al., 2004) . Expression of insulin, insulin-like growth factors (IGFs), and insulin-like growth factor binding proteins (IGFBPs) is altered in many neurodegenerative diseases, including AD (Tham et al., 1993) and ALS (Wilczak et al., 2003) , and Igfbp2 was downregulated in tau P301L brainstem. Activation of complement is associated with an early response in AD (Shen and Meri, 2003) , and complement component 1q g polypeptide (C1qg) is significantly increased in tau P301L spinal cord, with a similar trend in the cortex and brainstem of tau P301L mice (Table 1 ). In contrast, it was interesting to note that several genes enriched in tau P301L cerebellum were known to have protective properties in neurodegenerative conditions. As an example, Bcl2 is an extensively studied outer mitochondrial membrane protein that has antiapoptotic properties in a variety of systems, including the CNS (Gross et al., 1999) , and Lims1 is crucial for cell survival and protection of cells from apoptosis (Zhang et al., 2004) . Other genes regulated in the cerebellum, including Psa, had not previously been implicated as potentially neuroprotective, and were interesting as they represented potentially novel modifiers of tau or tau-induced neurodegeneration (Figure 2 ). Since cerebellum is among the least affected brain regions in AD and FTD brain, as well as in tau P301L mice, and several identified changes involve genes with neuroprotective roles, we hypothesized that the differential regulation in some cases might reflect transcriptional compensation that protected against tau-induced neurodegeneration. Gain-of-function alleles of such genes would be expected to be suppressors of tauopathy, whereas loss-of-function of alleles would be expected to exacerbate tau-induced neurodegeneration.
PSA as a Suppressor of Tau-Induced Neurodegeneration in Drosophila Misexpression of the longest 4-repeat isoform of human tau in Drosophila recapitulates pathological tau aggregation and neurodegeneration, including the formation of NFT and PHF when pathologically phosphorylated by a form of GSK-3b (Jackson et al., 2002) . In this model, At least three nonlittermate animals of each genotype were used, and the images depicted were taken from sagittal sections of six month old brains hybridized to 35 S-labeled antisense cRNAs. (B) Northern blot confirmation of microarray results in six genes of varying abundance using total RNA isolated from at least three independent nonlittermate animals of each genotype. Results are expressed as fold change for at least three animals each for tau P301L and control mice. The directions of expression patterns for all genes were in agreement with microarray data and were significant using two-tailed t tests (p < 0.01). Error bars, mean 6 standard deviation. (C) Sagittal sections show that Psa is specifically enriched in tau P301L cerebellum (arrows) relative to other regions, consistent with microarray and Northern data. SC, spinal cord; CB, cerebellum. tau expression produces a ''rough'' eye phenotype that reflects underlying neurodegeneration, as assessed by immunohistochemical staining in the larval eye disc, as well as neuronal loss and disorganization of the retina (Doglio et al., 2006; Jackson et al., 2002) . This model is relevant to disease, as nearly half of the known FTDcausing mutations alter tau splicing by increasing the ratio of 4-repeat tau to 3-repeat tau (Hutton et al., 1998; Jackson et al., 2002; Lee et al., 2001 ). In addition, expression of mutant tau P301L induces a similar phenotype (e.g., Figures 3 and 4) . We therefore used this fly model as an initial screen to provide a cross-species functional assessment. Remarkably, one of the genes, PSA, was identified in an independent pilot screen for modifiers of tau-induced neurodegeneration using the first fifty lethal transposon insertions on the third chromosome, which was obtained from the Bloomington Stock Center (http://flystocks.bio.indiana.edu). We obtained additional lines of PSA and two other genes identified from the microarray screen, Vapb and Eef1a1, which also modified neurodegeneration caused by tau misexpression in the fly eye (Figures 3 and 4 ).
These observations provided an initial functional assessment and confirmation that the genes identified in the microarray screen in mouse play potential functional roles in modifying tau-induced neurodegeneration since the tau interactions in fly were consistent with dysregulation in tau P301L mice (Table 1) . A loss-of-function mutation of fly Vapb, DVAP-33A (Pennetta et al., 2002) , suppressed neurodegeneration, consistent with its known role in human ALS (Nishimura et al., 2004) and the current microarray screen, in which it was upregulated in the brainstem, a vulnerable brain region ( Figure 3B ). Furthermore, a loss-of-function allele of EF1a48d, a fly homolog of Eef1a1, which was upregulated in the brainstem and thus postulated to confer tau vulnerability in the mouse, also suppressed the tau eye phenotype ( Figure 3C ), consistent with its potential role in sensitizing cells to apoptosis (Duttaroy et al., 1998) . We also identified a transposon insertion strongly enhancing the tau eye phenotype that was in the 5 0 UTR of Drosophila Psa (dPsa; Figure 4B ). Similar results were obtained using a bona fide mutation (Schulz et al., 2001) , consistent with the hypothesis based on microarray data Table 1 . Genes Differentially Expressed between P301L Tau and Control Brains Gene names are listed (http://www.ncbi.nlm.nih.gov) alongside the Genbank Accession numbers representing the sequences used to construct the microarray probes. CX, cortex; BS, brainstem; SP, spinal cord; CB, cerebellum. The column designated ''Method'' indicates the criteria used for selection of regulated genes. FC, 1.4-fold change in all biological replicates. FDR, 0.05% false discovery rate. Genes confirmed with Northern blot (NB) analysis or in situ hybridizations are indicated in the penultimate column. Genes highlighted in yellow were in both mouse and fly.
that overexpression of PSA would suppress, whereas loss of function of PSA would exacerbate, neurodegeneration ( Figure 4B ).
PSA Loss of Function Enhances Tau-Induced Neurodegeneration in Drosophila
Given the high expression of PSA in brain (McLellan et al., 1988; Tobler et al., 1997) and the recognition of the importance of the N terminus of tau in aggregation, coupled with a paucity of knowledge as to the proteolytic processing of tau (Gamblin et al., 2003; Lee et al., 2001) , we focused our further efforts on PSA. To more directly assess the mechanism by which PSA activity affected tau-induced neurodegeneration in vivo, we examined whether PSA loss of function affected the Drosophila tau eye phenotype using several distinct lines. In contrast to the mild rough eye observed with tau alone ( Figure 4A ), tau expressed in combination with a transposon insertion in the 5 0 UTR of dPSA produced a markedly enhanced phenotype ( Figure 4B ). Identical results were obtained using a large deletion of the PSA locus (data not shown). To assess whether PSA modifies the tau phenotype in a specific fashion, as opposed to having more general effects on neurodegenerative or cell death phenotypes, PSA loss-and gain-of-function lines were crossed with flies expressing a form of mutant huntingtin or the cell death gene reaper. No modification of either phenotype was observed ( Figure 5 ), suggesting that the effect of PSA is not due to a generalized effect on cell death, but rather due to a more specific effect on tau.
PSA Expression Affects Tau Levels and Neurodegeneration
To explore the relationship of PSA to tau pathology further, we next examined tau expression and distribution in vivo in transgenic flies. Mild loss of photoreceptor neurons was produced by the human tau transgene, along with aberrant neuronal polarity, as described in detail previously (Jackson et al., 2002) (Figure 4D ). Tau expression in a mutant dPsa background produced a more severe phenotype ( Figure 4E ). In contrast, lowlevel overexpression of dPSA reversed tau-induced neurodegeneration and abnormalities of polarity (Figure 4F) . We engineered new fly lines directly expressing tau under control of the glass (gl) promoter (Hay et al., 1995) . The mild neurodegenerative phenotype induced by tau alone ( Figure 4G ) was suppressed by overexpression of dPSA ( Figure 4H ), whereas the phenotype of the gl-dPSA eye was normal ( Figure 4I ). We next examined whether dPSA overexpression affected tau levels using immunohistochemical analysis of larval eye discs. WT phenotype (A) when expressed in trans to a P element allele of Psa (B), which has no phenotype on its own (C). (D-F), Confocal images of adult retina stained with TRITC-phalloidin (red) and anti-lamin D 0 (green). Photoreceptor loss and disorganization caused by gl-Tau WT (D) are enhanced in trans to a PSA mutation (E) but suppressed when Psa is overexpressed at low levels using hs-PSA at 25 C. (G-I) SEM images demonstrating suppression of the gl-Tau WT phenotype (G) using a direct fusion gl-Psa transgene (H), which has no eye phenotype on its own (I). (J-L) Confocal images showing reduction of tau staining in third-instar larval eye disc by Psa coexpression. Blue, anti-Elav; red, T14; green, anti-dPsa. Anterior is shown toward the left. In the presence of gl-Tau WT , tau expression (red) is apparent beginning at the morphogenetic furrow toward the left of the panel and is robust throughout the eye disc, even in posterior portions of the disc (J). When glPsa is coexpressed, however, posterior portions of the disc (bracket) show only residual tau (K). The gl-Psa transgene alone shows low levels of Psa staining (green), as expected (L). Scale bars, 100 Staining of the eye disc enables comparison of cells that have just begun to coexpress tau and dPSA (near the morphogenetic furrow) with those that have been expressing the two transgenes longer (toward the posterior of the disc). Although tau expression was apparent throughout the eye disc ( Figure 4J ), coexpression with dPSA resulted in loss of the majority of tau staining in posterior portions of the disc (bracket in Figure 4K ). The gl-dPSA disc was normal, with low levels of dPSA detected in the weak lines selected for use in these studies ( Figure 4L ). These data demonstrate that overexpression of dPSA led to a substantial reduction of tau protein in parallel with its apparent neuroprotective effect and suggest that this reduction in tau could underlie dPSA's modulation of tau-induced neurodegeneration.
PSA Robustly Suppresses the P301L Mutant Tau Phenotype
We next compared the effects of dPsa overexpression in eyes expressing tau WT and tau P301L in order to ascertain whether PSA was active against mutant tau, which is more pathogenic and prone to aggregation than wildtype tau (Arrasate et al., 1999; Rizzu et al., 1999) . Whereas mild suppression of the gl-Tau WT phenotype ( Figure 6A ) was observed with coexpression of gldPSA ( Figure 6B ), the gl-Tau P301L phenotype ( Figure 6C ) was more dramatically suppressed by gl-dPSA ( Figure 6D ). Mild photoreceptor loss and aberrant polarity produced by gl-Tau WT ( Figure 6E ) were largely suppressed by coexpression of gl-dPSA ( Figure 6F ). Moreover, the apparent reduction of tau protein by dPSA overexpression that was apparent at earlier stages (Figure 4) was also evident in the adult retina: the photoreceptor abnormalities induced by gl-Tau WT were accompanied by both diffuse and focal accumulation of tau ( Figure 6E ), whereas coexpression with dPSA resulted in a more diffuse pattern of tau staining ( Figure 6F ). Similarly, dPSA suppression of the tau P301L phenotype ( Figure 6G ) was accompanied by dramatic reductions in tau immunoreactivity ( Figure 6H ). We next compared the apparent reductions in both tau WT levels observed using immunohistochemistry and Western blotting (Figures 6I and 6J ). Representative Western blots showed reduced levels of both tau WT and tau P301L in flies coexpressing dPSA; these differences are observed with antibodies recognizing several distinct epitopes in tau ( Figures 6I and 6J ). Densitometric analysis revealed significant reductions in both tau WT (p < 0.05) and tau P301L (p < 0.001) levels by coexpression of dPsa ( Figure 6I ). These findings demonstrate that PSA is a previously unidentified modifier of neurotoxicity induced by tau misexpression or human disease-causing mutations and can diminish tau accumulation in vivo.
PSA Digests Tau In Vitro
The known function of PSA as an aminopeptidase, comprising over 90% of the aminopeptidase activity in the brain (McLellan et al., 1988) , and the diminution of tau immunoreactivity in parallel with PSA overexpression observed here suggested that PSA acts directly on the amino terminus of tau via its peptidase activity. However, it was plausible that PSA had no direct interaction with tau, and was acting via cleavage of another intermediary. We therefore determined whether recombinant human PSA could cleave the longest isoform of human tau in a cell-free system. After 4 hr of incubation with PSA, full-length tau was partially diminished to w65% of its original level, concomitant with the appearance of low-molecular weight, immunoreactive products likely representing the products of partial digestion (Figures 7A and 7B ). Over the next 16 hr, this process continued, until after 18-20 hr of incubation, tau was digested completely by PSA. This process was inhibited by the specific PSA inhibitor puromycin and the more general aminopeptidase inhibitor bestatin ( Figures 7C  and 7D ), providing confirmation that the observed tau degradation was due to the protease activity of PSA. Quantification of Western blots indicates that 90% of tau was digested by PSA, and that up to 90% of the tau was prevented from degradation by the inhibitors ( Figure 7D ). The observation that purified human PSA can directly cleave and significantly diminish human tau in vitro is consistent with data from Drosophila in vivo.
PSA Expression in Human Cortex and Cerebellum
We performed Western blotting using protein extracts from postmortem cortex and cerebellum of FTD cases (n = 6) and human controls (n = 6; see Table S1 in theSupplemental Data) to assess PSA protein levels in human brain. Remarkably, PSA expression was elevated 5-fold in the cerebellum as compared with frontal cortex in both controls and FTD cases ( Figure 8A ; normalized to b-tubulin). Comparison of PSA levels between FTD and controls showed a small but significant elevation of PSA in frontal cortex in FTD brains (see Figure S1 in the Supplemental Data). Immunohistochemistry confirmed previous observations that PSA is expressed primarily in neurons (Hui and Hui, 2003; Minnasch et al., 2003; Schonlein et al., 1994) , as demonstrated by colocalization with the neuronal nuclear marker NeuN (Figures 8B and 8C) . The qualitative immunohistochemical data support the more quantitative Western blot data, indicating that at the cellular level, PSA is increased in human cerebellum neurons relative to frontal cortical neurons (Figure 8 ).
Discussion
Here we use microarray analysis to identify genes whose expression is altered in conjunction with patterns of regional vulnerability in a mouse model of FTDP-17. We provide independent confirmation of a subset of these genes by Northern blotting and in situ hybridization and perform in vivo functional validation in another animal model, Drosophila. This work provides a clear proof of principle for validation of genetic screens using model systems and allows us to more firmly establish a functional role for one of the identified genes, Psa. Although Psa was known to be highly brain-enriched, to our knowledge, its role vis-a-vis tau degradation or modification of tau-induced neurodegeneration has not been characterized previously. We show that in the fly model, dPsa modulation of neurodegeneration is not likely to be a phenomenon related to a general or nonspecific suppression of cell death, as its overexpression or mutation has no observable effect on two other fly phenotypes. Furthermore, we show that human PSA can directly degrade human tau in vitro via its aminopeptidase activity, which is consistent with in vivo data in the fly showing that PSA overexpression coincides with loss of tau immunoreactivity.
Identification of genes likely to have functional relevance based on data derived from microarray experiments is often difficult, so independent confirmation and some degree of functional validation are needed to provide confidence in the significance of microarray results. However, confirming modifiers of late-onset neurodegenerative phenotypes in mice can be burdensome; hence, intermediate steps involving careful prioritization of potential targets are necessary. Although genetic modifiers of tauopathy in the fly have been identified (Shulman and Feany, 2003) , functional validation of these modifiers in mammalian systems has not yet been reported. The combination of two distinct genetic screens in model organisms described here provides an efficient way to approach discovery of novel disease modifiers. Data derived from in vivo studies with animal models and a cell-free system suggest that PSA may play a pivotal role in protection from tau-induced neurodegeneration, most likely by direct cleavage of tau. Tau levels are inversely correlated with PSA levels in vivo in the fly, and purified human PSA cleaves tau in a cellfree system. These data validate the use of Drosophila to screen for potential modifiers of disease, as this model organism provides an efficient and economical means for in vivo functional assessment of disease modifiers identified by microarray screening in mice.
In contrast to Psa, expression of Vapb, a vesicle trafficking protein, was elevated in tau P301L mouse brainstem, and thus this gene was considered as a potential enhancer or mediator of tau-induced neurodegeneration. This finding was notable as mutations in Vapb cause autosomal dominant motor neuron disease (Nishimura et al., 2004) , supporting its potential involvement in neurodegeneration. It is also important to note that clinically apparent motor neuron disease is observed in 15% of patients with FTDP-17, and more have subclinical, pathological signs of motor neuron degeneration (Lee et al., 2001; Lomen-Hoerth, 2004 ). Here we show that Vapb mRNA was upregulated in a vulnerable region in tau P301L mice, whereas a loss-of-function mutation of the fly homolog suppressed the tau phenotype in the fly. Hence, Vapb provides a potential link between tauopathy and motor neuron disease in FTD that is worthy of further investigation.
Eef1a1, a ubiquitously expressed component of the translation initiation complex, was also identified in this study as being upregulated in the brainstem. Previous literature suggests that it may serve as a pro-or antiapoptotic factor in different systems (Chen et al., 2000; Duttaroy et al., 1998; Talapatra et al., 2002) . These data are consistent with the notion that elevated expression of Eef1a1 is associated with susceptibility to tauinduced neurodegeneration. A loss-of-function allele of the Drosophila homolog strongly suppressed the tau phenotype, consistent with the notion that Eef1a1 is a prodegenerative factor.
Deciphering which of the observed changes in a microarray study are most relevant to the neurodegeneration observed in the human disease is a complex task (Geschwind, 2000; Small et al., 2005) . Here we have applied a powerful filter to the data, focusing our downstream efforts primarily on expression changes in a region that, despite expressing high levels of the mutant gene of interest, exhibits no overt signs of neurodegeneration. In this manner, we were able to identify several genes with putative neuroprotective roles.
It has been suggested previously that amino terminal caspase-mediated cleavage of tau in vitro and in AD cases may be involved in NFT formation (Amadoro et al., 2004; Gamblin et al., 2003) . Moreover, FTDP-17 mutations may render tau protein less susceptible to proteolysis, increasing the propensity of tau to form aggregates, consistent with the protective effects of PSA-mediated tau proteolysis. The observation here that Psa can also control tau toxicity in vivo supports the identification of this enzyme as a regulator of tau-induced neurodegeneration, perhaps analogous to the role of proteolytic processing of other potentially toxic moieties, such as proteolytic processing of amyloid by presenilins or secretases (Hardy and Selkoe, 2002; Sisodia and St George-Hyslop, 2002) .
A large body of evidence indicates that regulation of amyloid precursor protein (APP) and its proteolytic fragments plays a critical role in AD pathogenesis (Sisodia and St George-Hyslop, 2002) . Similarly, it is clear from the human FTD-causing mutations that even relatively subtle changes in tau isoform levels can cause neurodegeneration (D'Souza and Schellenberg, 2005). Conversely, turning off an inducible mutant tau P301L transgene after the onset of severe tau pathology in the mouse, thereby reducing mutant tau levels, can reverse the neurodegenerative process (Santacruz et al., 2005) . Thus, it is tempting to speculate that factors that act to modulate tau levels or splicing, such as PSA, are candidates for playing a causal or contributory role in disease, and may represent potential targets for development of therapeutics. As an example, factors that lead to PSA downregulation in humans would be expected to increase tau, which in turn could contribute to disease susceptibility. The relatively high level of PSA expression, while correlative, within human cerebellar neurons ( Figure 8A ), which are less affected than cerebral cortex in AD and FTD, is consistent with this hypothesis. In addition, preliminary experiments assessing tau deposition and PSA levels by immunohistochemistry in postmortem cortical tissues from AD and FTD patients suggests an inverse relationship between PSA expression and tau deposition in neurons (data not shown). Similarly, we postulate that the trend toward a relative increase in PSA in postmortem FTD frontal cortex relative to controls (Figure S1) may reflect its higher level of expression in neurons surviving after a long course of disease. Neurodegeneration in FTD is known to primarily affect the superficial cortical laminae, so even within brain regions, different neurons are likely to show distinct patterns of vulnerability to neurodegeneration. The data described here provide a set of initial observations highlighting a potential role for PSA that warrant further analysis in other models and in human patient samples.
It is notable that PSA has been coimmunoprecipitated with APP (Schonlein et al., 1994) and colocalized around senile plaques in the cerebral cortex and hippocampus of AD brain (Minnasch et al., 2003) . Although PSA does not directly alter APP levels in vitro, it is tempting to speculate that PSA could also provide a link between amyloid deposition and tau pathology observed in AD. While this and other questions relevant to the causal role of PSA in a spectrum of human diseases involving tau will be important to answer in future, its discovery as a protease potentially mediating tau degradation is an important step forward in understanding the pathogenesis of tauopathies and developing new therapeutic interventions in these fatal neurodegenerative diseases.
Experimental Procedures
Mice, Tissue Dissections, and RNA Isolation Tau P301L mice (Lewis et al., 2000) were housed in groups of up to four and kept on a 12 hr light/dark cycle at 22 C. Food pellets and water were available ad libitum. All animal protocols were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the UCLA animal studies committee. For gene expression experiments, the brains of 12 six-month-old tau P301L and 12 nontransgenic males were dissected, separating the spinal cord, cortex, brainstem, and cerebellum ( Figure 1A ). Total RNA was extracted using acid phenol extraction (Trizol LS; GIBCO/ BRL). The concentration and quality of RNA were determined using the Nanodrop spectrophotometer and confirmed on the Agilent bioanalyzer.
Microarray Data Analysis
All studies used the Agilent Developmental oligonucleotide microarray containing over 20,273 unique probes, representing 10,039 (49.5%) genes with a known full-length cDNA sequence (including 1584 RIKEN genes) and an additional 6289 (31.0%) ESTs. cDNA synthesis, cRNA labeling, hybridization, and scanning were performed according to the manufacturer's protocol (Agilent). To minimize sample variability caused by individual differences between animals and dissections, RNA from at least three male littermates of the same genotype was pooled for preparation of each region-specific pool (Figure 1 ). Experimental tau P301L pools were compared to littermate nontransgenic control pools. The comparisons were performed in three different litters, therefore producing three independent biological replicates. In total, we obtained 24 expression profiles for cortex, spinal cord, brainstem, and cerebellum of tau P301L and control animals. The raw microarray data were analyzed in the R statistical package (http://lib.stat.cmu.edu/R/CRAN/index.html). The local background values were subtracted from the raw signal intensity values and transformed as log 2 , which allows a natural interpretation of differential expression as fold changes and makes the intensity distribution more symmetric and the error variances more homogeneous. The log 2 intensities below the mean + 2.64 standard deviations of negative control intensities in each array were excluded from further analysis. The contrast-based cyclic lowess normalization method was used in the groups corresponding to a specific brain region (Bolstad et al., 2003) . Normalizations were carried out in all distinct pairwise comparisons. Two different methods were used to identify differentially expressed genes. First, the local-pooled-error (LPE) method was used. The LPE method is known to be appropriate for a small number of replicated microarrays (Jain et al., 2003) . The LPE was derived by evaluating the baseline error distribution in each brain region. Then, the median for each gene under the two comparison conditions was calculated. The LPE statistics for the median difference were calculated as
where Med i , i = 1,2 is the median intensity of the mutant and wildtype, respectively;
where n 1 and n 2 are the number of replicates in the two conditions; and
is the estimate of the variance from each LPE baseline-error distribution at each Med i . The LPE statistic Z follows an approximately normal distribution under the null hypothesis that the gene is not significantly different between two compared conditions. Thus, the raw p values were obtained for each gene (see Supplemental Data). The Benjamini and Hochberg false discovery rate was evaluated using a p value of 0.05 to adjust for multiple comparisons. In the second method, normalized expression levels were used to generate ratios of experimental/control signals. The genes with R0.5 or %20.5 ratios (1.4-fold change) through all replicates were selected as regulated (Table 1 ). This criterion was based on the 99.5% confidence interval derived from homotypic hybridizations (data not shown; as in Lobo et al., [2006] ). Genes identified using at least one of the methods were considered to be regulated. For details regarding additional experimental design and methods, see MIAME report and http://geschwindlab.medsch.ucla.edu.
Northern Blot Analysis
For Northern blotting, total RNA was extracted from the cortex, cerebellum, brainstem, and spinal cord from at least three transgenic and three control male mice, all nonlittermates. Blots were prepared using 10 mg of total RNA and transferred to a Nytran SPC membrane (Schleicher & Schuell) . Probe labeling, hybridization, and washes were done using the Strip-EZ protocol (Ambion). The Phosphor Imager system (Molecular Dynamics) was used to visualize and quantify the probe signals. For normalization controls, a b-actin probe was used.
In Situ Hybridization
In situ hybridizations were performed using six-month-old tau P301L and control animals as described previously (Geschwind et al., 2001) . Slides contained at least three sagittal sections through entire brains of either control or tau P301L mice.
Drosophila Genetics and Phenotypic Analysis
A transposon insertion in the 5 0 UTR of dPSA (l(3)06226) was identified initially as a tau enhancer in a pilot screen of lethal P element insertions on the third chromosome obtained from the Bloomington Stock Center (Bloomington Stock number 10158; http://flybase. org/.bin/fbidq.html?FBst0010158). (For listing of stocks see http:// flystocks.bio.indiana.edu/Browse/insertions/GDP_all/pz-3.htm). Individual males for each P lethal line (maintained over balancer chromosomes) were crossed to females of the genotype y 1 w 1118 ; glTau WT -1.1 (Jackson et al., 2002) ; control crosses used y 1 w 1118 males. Eye phenotypes of progeny were scored under the dissecting microscope, and positive ''hits'' were evaluated further using scanning electron microscopy (SEM). Enhancers tend to decrease eye size and produce eyes with a more uniform rough appearance, (i.e., leading to fusion and loss of ommatidia), whereas suppressors increase size and tend to have the rough area confined to the most anterior portions of the eye. Findings using (l(3)06226) were subsequently confirmed using a characterized allele of PSA, PX49 (Schulz et al., 2001) . Ubiquitous low-level overexpression of dPSA was accomplished using a heat shock (hs)-dPSA line and raising progeny at 25 C. To engineer the gl-dPSA line, dPSA was subcloned into pExpress-gl. Identity of the construct was confirmed by sequencing. Transgenic lines were obtained using standard techniques Spradling and Rubin, 1982) . As some gldPSA lines had abnormal phenotypes, we selected for lines with weak expression of dPSA in order to demonstrate clear genetic suppression. The DVAP33A mutant, which was produced using imprecise excision, was obtained from Hugo Bellen (Pennetta et al., 2002) , and the piggyBac insertion (Thibault et al., 2004) in Eef1a1 was obtained from the Bloomington Stock Center. The UAS-htt-Q120 1-78 construct was derived from GMR-htt-Q120 1-171 (Jackson et al., 1998) .
Analysis of eye phenotypes using scanning electron microscopy was performed as described previously (Sang et al., 2005) . Analysis of adult retinal phenotypes using whole-mount preparations in conjunction with laser scanning confocal microscopy was performed as described previously (Jackson et al., 2002; Sang et al., 2005) . Samples were stained with TRITC-phalloidin (Sigma) and either antilamin D 0 (Smith and Fisher, 1989) (1:200) or T14 (Kosik et al., 1988) (1 mg/ml; Zymed), in conjunction with FITC-anti-mouse IgG. Immunohistochemical analysis of the larval eye disc was carried out using established procedures (Jackson et al., 2002; Sang et al., 2005) . Samples were stained with T14 + TRITC-anti-mouse, anti-dPSA antiserum (1:100) + FITC-anti-rabbit, or anti-Elav (Robinow and White, 1988) (1:100) + Cy5-anti-rat IgG. The dPSA antiserum was raised against a peptide (CQRDREQLAIFFRDDQ) and generated commercially (Open Biosystems); it was found to react specifically with dPSA in immunohistochemistry and Western blots (data not shown). Secondary antibodies were from Jackson Immunoresearch.
Western Blotting
Crude protein extracts from postmortem frontal cortex and cerebellum of six FTD and six control brains were used (Table S1 ). The tissues were homogenized in hypotonic buffer and a protease inhibitor cocktail (Roche). Fly heads were homogenized in 10 mM Tris-HCl (pH 7.4) + 0.8 M NaCl + 1 mM EGTA (pH 8.0) + 10% sucrose and a protease inhibitor cocktail (Roche). Protein concentrations were determined by the Bradford assay (Bio-Rad) and samples containing approximately equal protein concentrations were loaded. Proteins were separated by SDS-PAGE using a 4%-20% Tris-HCl gel, transferred to nitrocellulose membranes, and incubated overnight at 4 C with goat anti-rat PSA (1:500), T14 (1:1000), AT8 (Biernat et al., 1992) (1:1000; Pierce), Tau5 (Carmel et al., 1996) (1:10,000), and/or anti-btubulin (1:1000, Accurate Science). Filters were treated with peroxidase-conjugated anti-goat (1:5000) or anti-mouse (1:2000) IgG and signal detected using chemiluminescence. Blots were scanned and quantitated using NIH ImageJ (http://rsb.info.nih.gov/ij/). Data were compiled from at least three separate experiments. Data were plotted using Sigmaplot, and two-way ANOVA with Bonferroni's post hoc comparison was carried out using Sigmastat.
Immunohistochemistry
The UCLA Department of Pathology provided formaldehyde-fixed and paraffin-embedded human postmortem brain tissue under UCLA human subject guidelines. Primary antibodies used in the study include goat anti-rat PSA serum (1:10) and mouse anti-neuronal nuclei (NeuN) monoclonal antibody (1:100) (Chemicon). Microwave boiling of deparaffinized sections in 0.015 M sodium citrate buffer (pH 6.0) for 12 min was employed as an antigen retrieval procedure. Sections were incubated overnight first with anti-NeuN, followed by incubation with the Vector ImmPRESS mouse reagent, and developed using the Vector Labs VIP kit. Sections were then reacted overnight with goat anti-rat PSA antiserum, followed by incubation with biotinylated horse anti-goat secondary antibodies (1:500) and development using the avidin-biotin complex kit (ABC; Vector Labs) and Vector DAB reagent. The slides were counterstained with Vector Methyl Green.
PSA Preparation and Enzymatic Activity
The cDNA corresponding to human PSA (hPSA) was generated by PCR from the Large Insert Human Brain cDNA library (Clontech) and ligated into the pET-41 Ek/LIC vector (Novagen) having an N-terminal glutathione S-transferase (GST) fusion tag. The pET-41-GSThPSA construct was then transformed into E. coli BL-21-DE3* cells (Novagen). To reduce the extent of inclusion body formation, cells were grown at 18 C for 16 to 17 hr after induction by IPTG. Cells containing soluble PSA were harvested, resuspended in phosphate buffer (pH 7.3), and disrupted using a French press. After centrifugation, the supernatant was applied to a glutathione Sepharose column, and eluted fractions containing hPSA activity were pooled and further purified on a Superdex-200 column. The soluble, purified GST-PSA migrated largely as a single band on SDS-PAGE (data not shown). Enzymatic activity was assayed at 37 C using amino acid pnitroanilides of Lys, Ala, Met, Leu, Val, and Pro on a Beckman DU 640 spectrophotometer employing a modified colorimetric assay (Constam et al., 1995) .
Tau Preparation and Digestion with PSA Expression and purification of full-length recombinant human tau protein was performed as described previously (Goedert et al., 1989) . For time course analysis, digestion of 6XHis-Tau was carried out at 37 C in 10 mM Tris-HCl buffer (pH 7.4), containing 1 mM DTT at a molar ratio of 1:14.2 (PSA:tau). Aliquots were taken at 0, 4, 8, 12, 14, 16, 18 , and 20 hr, and the reaction was terminated by the addition of Laemmli SDS sample buffer and boiling for 5 min. Samples were analyzed by electrophoresis on a 10%-20% SDS-PAGE gradient gel. Proteins were transferred to nitrocellulose and the membrane was immunostained with the C-terminal-specific antibody Tau-46.1 (Carmel et al., 1996) (1:50,000). Horseradish peroxidase (HRP)-conjugated secondary antibody (Vector Laboratories) and enhanced chemiluminescence (Amersham Biosciences) were used to visualize the bands.
For inhibitor experiments, digestion of tau was carried out at 37 C for 20 hr in 10 mM Tris-HCl buffer (pH 7.4) containing 1 mM DTT at a molar ratio of 1:14.2 (PSA:tau). Proteins were electrophoresed and transferred to nitrocellulose membranes, which were incubated with Tau-7, which recognizes the C-terminal portion of tau. Inhibition experiments were carried out using puromycin (Sigma), a specific inhibitor of PSA, or a general inhibitor of aminopeptidases, bestatin (Sigma). The inhibitors were incubated for 5 to 10 min at room temperature prior to the addition of tau protein and digestion as described above.
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